Caribou Biosciences Inc CRBU
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-23 |
| Shares Out. | 99,180,000 |
| Website | cariboubio.com/ ↗ |
| Phone | 15109826030 |
| Employees | 97 |
| Revenue | $2.4M |
| Gross Profit | $2.4M |
| Net Income | -$25.1M |
| Free Cash Flow | -$101.6M |
| Total Assets | $149.0M |
| Total Liabilities | $47.0M |
| Equity | $102.0M |
About Caribou Biosciences Inc
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Caribou Biosciences Inc is a publicly traded company under the ticker symbol CRBU on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)